Evidence map›Paper›PMID 38612563›Full record

ArticleInternational journal of molecular sciences2024

Circulating Cancer-Associated Macrophage-like Cells as a Blood-Based Biomarker of Response to Immune Checkpoint Inhibitors.

Valentina Magri, Gianluigi De Renzi, Luca Marino, Michela De Meo, Marco Siringo, Alain Gelibter, Roberta Gareri, Chiara Cataldi, Giuseppe Giannini, Daniele Santini and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Circulating Tumor Cell PD-L1 and Peripheral Blood CD8Cancer management and research · 2026
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Valentina MagriDepartment of Pathology, Oncology and Radiology, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0001-7312-2904
Gianluigi De RenziDepartment of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Luca MarinoDepartment of Mechanical and Aerospace Engineering, Sapienza University of Rome, 00184 Rome, Italy.ORCID 0000-0001-7380-6222
Michela De MeoDepartment of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-3024-2233
Marco SiringoDepartment of Pathology, Oncology and Radiology, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-0489-1790
Alain GelibterDepartment of Pathology, Oncology and Radiology, Sapienza University of Rome, 00161 Rome, Italy.
Roberta GareriUOC di Oncologia Medica, Ospedale Leopoldo Parodi Delfino, 00034 Colleferro, Italy.
Chiara CataldiDepartment of Pathology, Oncology and Radiology, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-9938-6403
Giuseppe GianniniDepartment of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0003-0299-4056
Daniele SantiniDepartment of Pathology, Oncology and Radiology, Sapienza University of Rome, 00161 Rome, Italy.
Chiara NicolazzoDepartment of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-2551-8979
Paola GazzanigaDepartment of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-2325-2273
Sapienza University of Rome · IT

Funding

European Union CUP B53C22004000006Sapienza University of Rome RM119116B311436754
6 · The paper itself

Abstract

Evidence has been provided that circulating cancer-associated macrophage-like cell (CAM-L) numbers increase in response to chemotherapy, with an inverse trend compared to circulating tumor cells (CTCs). In the era of evolving cancer immunotherapy, whether CAM-Ls might have a potential role as predictive biomarkers of response has been unexplored. We evaluated whether a serial blood evaluation of CTC to CAM-L ratio might predict response to immune checkpoint inhibitors in a cohort of non-small-cell lung cancer patients. At baseline, CTCs, CAM-Ls, and the CTC/CAM-L ratio significantly correlate with both progression-free survival (PFS) and overall survival (OS). The baseline CTC/CAM-L ratio was significantly different in early progressors (4.28 ± 3.21) compared to long responders (0.42 ± 0.47) (

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoplastic Cells, CirculatingBiomarkersHumansImmune Checkpoint InhibitorsMacrophagesPilot ProjectsBiomarkersImmune Checkpoint InhibitorsCellSearch®circulating cancer-associated macrophage-like cellscirculating tumor cellsimmunotherapynon-small-cell lung cancer

Identifiers

PMID38612563
PMCPMC11011814
OpenAlexW4393255764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.